|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATION
|
|
|
|
|
|
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer |
Daniel Spratt, MD
|
Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Dr. Spratt and colleagues sought to acquire the most up-to-date data on the evidence for the Decipher® test which now has substantial evidence to support its clinical use with over 42 studies with 30,000 patients in these studies spanning localized prostate cancer from low to high-risk, as well as post-prostatectomy.
|
|
|
|
|
|
|
|
|
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer - European Urology Abstract
|
Neil K Jairath, Alan Dal Pra, Randy Vince, Robert T Dess, William C Jackson, Jeffrey J Tosoian, Sean M McBride, Shuang G Zhao, Alejandro Berlin, Brandon A Mahal, Amar U Kishan, Robert B Den, Stephen J Freedland, Simpa S Salami, Samuel D Kaffenberger, Alan Pollack, Phuoc Tran, Rohit Mehra, Todd M Morgan, Adam B Weiner, Osama Mohamad, Peter R Carroll, Matthew R Cooperberg, R Jeffrey Karnes, Paul L Nguyen, Jeff M Michalski, Jonathan D Tward, Felix Y Feng, Edward M Schaeffer, Daniel E Spratt
|
Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer. Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use. The aim of this study was to perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier.
|
|
|
|
|
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
|
Felix Y. Feng, MD; Huei-Chung Huang, MA; Daniel E. Spratt, MD; Shuang (George) Zhao, MD; Howard M. Sandler, MD; Jeffry P. Simko, MD, PhD; Elai Davicioni, PhD; Paul L. Nguyen, MD; Alan Pollack, MD, PhD; Jason A. Efstathiou, MD, PhD; Adam P. Dicker, MD, PhD; Tamara Todorovic, MSc; Jennifer Margrave, BSc; Yang (Seagle) Liu, PhD; Bashar Dabbas, MD; Darby J. S. Thompson, PhD; Rajdeep Das, MD, PhD; James J. Dignam, PhD; Christopher Sweeney, MD; Gerhardt Attard, PhD; Jean-Paul Bahary, MD; Himanshu R. Lukka, MD; William A. Hall, MD; Thomas M. Pisansky, MD; Amit B. Shah, MD; Stephanie L. Pugh, PhD; William U. Shipley, MD; Phuoc T. Tran, MD, PhD
|
In this ancillary study of 352 men randomized to placebo or hormone therapy in the NRG/RTOG 9601 clinical trial of salvage radiation, the Decipher genomic classifier was independently associated with the risk of metastasis, prostate cancer–specific mortality, and overall survival. These findings suggest that the Decipher genomic classifier is a promising biomarker to risk stratify men to better enable hormone therapy treatment decisions for biochemical recurrence of their prostate cancer after surgery.
|
|
|
|
|
Use of Genomics to Guide Treatment Decisions in Post-Prostatectomy Patients |
Ashley Ross, MD, Ph.D. |
Ashley Ross discusses the use of genomics to guide treatment decisions in post-prostatectomy patients. Dr. Ross highlights the recent European Urology paper assessing the clinical utility of the Decipher® genomic classifier, as well as three clinical trials that demonstrate that early salvage radiotherapy is preferred to adjuvant radiotherapy. |
|
|
|
|
|
|
|
|
Biomarkers to Guide Primary and Systemic Treatment for High-Risk Localized Prostate Cancer |
Felix Feng, MD
|
In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Optimizing Cure for High-Risk Clinically Localized Prostate Cancer”, Dr. Felix Feng from the University of California San Francisco’s Helen Diller Family Comprehensive Cancer Center presented a plenary talk discussing biomarkers to guide primary and systemic therapy for patients with high-risk localized prostate cancer. He sought to cover three main topics: the role of biomarkers in treatment naïve patients, the role of biomarkers following prostatectomy, and the role of germline testing. |
|
|
|
|
|
|
|
|
|